66
Participants
Start Date
October 31, 2016
Primary Completion Date
April 30, 2019
Study Completion Date
April 30, 2019
Totum-63
Each randomized subject will consume 8 capsules daily of either active (5200 mg of Totum-63) during 24 weeks (from visit V1 to visit V3). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.
Placebo
Each randomized subject will consume 8 capsules daily of placebo (5064 mg of maltodextrine) during 24 weeks (from visit V1 to visit V3). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.
Clinical Center of Vojvodina / Poseidon CRO, Novi Sad
Biofortis Mérieux NutriSciences Clinical Investigation Center, Saint-Herblain
Institut Pasteur de Lille, Lille
Atlantia Food Clinical Trials, Cork
Clinical center of Kragujevac, / Poseidon CRO, Kragujevac
University Medical Centre Ljubljana / Poseidon CRO, Ljubljana
Biofortis Mérieux NutriSciences
OTHER
Institut Pasteur de Lille
OTHER
Valbiotis
INDUSTRY